Navigation Links
1 step back ... 2 steps forward
Date:9/5/2008

Washington, DCWomen with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposiummay change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.

The strategy being investigated involves breast cancers that are fueled by estrogenthese are called estrogen-receptor or progesterone-receptor positive cancers (ER or PR positive). Women who have ER or PR positive metastatic breast cancer often take anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer from progressing. Aromatase inhibitors lower the amount of estrogen in the body. Over time, however, the cancer becomes resistant to this approach and begins to grow.

"At first, the tumor's growth is halted because the aromatase inhibitor is depriving the cancer of the estrogen it needs to grow," says Claudine Isaacs, M.D., clinical director of breast cancer program at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center. "Eventually, though, the cancer will figure out another way to thrive in the absence of the estrogen."

Isaacs and her colleagues, including lead author Deepa Subramaniam, M.D. of Lombardi, are conducting a clinical trial to see if a new approach can destroy the machinery the tumor creates in order to grow without the estrogen. The drug being studied is called sorafenib.

The results of the phase II study involving 27 patients were presented today at the ASCO 2008 Breast Cancer Symposium. It included post-menopausal women with metastatic breast cancer whose cancer had recurred or progressed while taking the aromatase inhibitor anastrozole. The preliminary analysis shows a clinical benefit response in 26 percent of the patients taking both sorafenib and anastrozole.

"Given what we know about the ineffectiveness of sorafenib alone in metastatic breast cancer, we believe the benefit that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," Isaacs concludes. "To manage breast cancer long term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach. In a sense, for each step back, we hope to take two steps forward."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. On September 7th Local Organizations Partner to Celebrate Healthy Steps
3. Americas Next Top Model Steps up for Psoriasis Awareness
4. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
5. Kmart Steps Out to Fight Diabetes
6. PDHI Launches ConXus Steps to Deliver Online Health Action Plans
7. YMCAs Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During America On the Move Week with the YMCA
8. American Diabetes Association Steps Up to Fight Diabetes
9. Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections
10. Six Simple Steps to Protect Against and Stop the Spread of Superbugs
11. Five Steps to Pop the Cork - Not Your Eye Out
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
Breaking Medicine Technology: